Clinical Trials

Clinical Trials

  Section Menu

CIMAvax Vaccine

Roswell Park has launched the first clinical trial in the U.S. to study the CIMAvax-EGF ® vaccine, a lung cancer treatment. Learn more about CIMAvax.

A clinical trial is a study designed to evaluate a promising new medical treatment. It includes research done to evaluate new ways to prevent and diagnose and/or treat cancer. At Roswell Park, up to 50% of our patients are eligible to enter clinical trials. Many types of treatment can be tested including:

  • New ways of preventing cancer such as drugs, diet, and/or exercise
  • New drugs to treat cancer
  • New ways to use existing treatment such as surgery or radiation therapy

When clinical trials identify new and effective treatments, these treatments will eventually become the new standard of care that will be offered to future patients. Today’s standard treatments were researched and proven by clinical trials done in the past.

Should I participate in a clinical trial? (Learn more about clinical trials from the NCI.)

Recently Opened Clinical Trials

A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Principal Investigator:
Wang, Eunice S
NCI EDDOP #10017, A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Principal Investigator:
Odunsi, Adekunle O
(ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Principal Investigator:
Twist, Clare J
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Principal Investigator:
Zsiros, Emese
A Phase I Study of pevonedistat (MLN4924, TAK924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma
Principal Investigator:
Hernandez-Ilizaliturri, Francisco J
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma
Principal Investigator:
Fountzilas, Christos
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma
Principal Investigator:
Puzanov, Igor
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Principal Investigator:
George, Saby
PHASE 1 STUDY OF DS-3032B IN COMBINATION WITH QUIZARTINIB IN SUBJECTS WITH FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA THAT ARE RELAPSED/REFRACTORY, OR NEWLY DIAGNOSED AND UNFIT FOR INTENSIVE CHEMOTHERAPY
Principal Investigator:
Wang, Eunice S
A Phase Ib Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX727 (Cedazuridine and Decitabine) in Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia
Principal Investigator:
Griffiths, Elizabeth A
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification...
Principal Investigator:
McCarthy, Philip L
(NRG-DT001) A Phase IB Trial Of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS)
Principal Investigator:
Kane, John M
NRG-GYN 005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or...
Principal Investigator:
Lele, Shashikant B
MM-310-01-01-01: A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients with Solid Tumors
Principal Investigator:
Ernstoff, Marc S
(S1802) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Principal Investigator:
Chatta, Gurkamal S
A randomized phase II study to evaluate efficacy of TDM1with or without Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer
Principal Investigator:
Opyrchal, Mateusz
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Principal Investigator:
Opyrchal, Mateusz
Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Principal Investigator:
Barth, Matthew J
Comparing Unilateral and Bilateral Deep Inferior Epigastric Perforators (DIEP) Flaps for unilateral breast reconstruction
Principal Investigator:
Moon, Wong K
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors
Principal Investigator:
Puzanov, Igor
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects with Relapsed and/or Refractory B Cell Lymphoma
Principal Investigator:
Hernandez-Ilizaliturri, Francisco J
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors with a Specific KRAS Mutation (AMG 510 20170543).
Principal Investigator:
Dy, Grace K
(ALTE16C1) Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Principal Investigator:
Rokitka, Denise A
(APL2-302) A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Principal Investigator:
Griffiths, Elizabeth A
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma
Principal Investigator:
Grand'Maison, Anne C
(EAE161) Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Principal Investigator:
Lele, Shashikant B
MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC
Principal Investigator:
Levine, Ellis G
MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Principal Investigator:
Levine, Ellis G
A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) after a Nonmyeloablative Conditioning Regimen, with...
Principal Investigator:
Odunsi, Adekunle O
Preoperative Respiratory Muscle Training to Prevent Postoperative Pulmonary Complications in Patients Undergoing Resection for Lung Cancer
Principal Investigator:
Yendamuri, Sai S